MLH1 and ovarian cancer: DNA isolated from plasma of patients suffering from ovarian cancer has been used to monitor CpG island methylation changes, and it was observed that methylation of the MLH1 promoter increased at relapse and predicted a poor clinical outcome following different chemotherapy regimens, including the platinum drug carboplatin, which induces the same DNA lesions as cisplatin [61].